新興市場：沙烏地阿拉伯的藥品市場

新興市場：沙烏地阿拉伯的藥品市場 是由出版商Datamonitor在2009年06月所出版的。 這份英文市場調查報告書包含123 pages 價格從美金5700起跳。

簡介

目錄

Abstract

Introduction

The Saudi Arabian pharmaceutical sector is becoming increasingly attractive for multinationals to enter driven by the expansion of private healthcare and altering patient demographics; and also for domestic generics companies as the government looks to evolve its cost saving strategies.

Scope of this research

• Overview of challenges faced by the Saudi Arabian healthcare system and a review of the healthcare financing system reforms
• Analysis of trends observed in the pharmaceutical sector and the development of the healthcare insurance sector
• Update of healthcare reforms undertaken in the Kingdom and thought-leader insights into future changes to be implemented
• Commercial implications of the reforms for insurers, multinational and domestic pharma companies, supported by Datamonitor strategic recommendations

Research and analysis highlights

Healthcare reforms in Saudi Arabia will increase access to healthcare services and pharmaceuticals as the penetration of cooperative health insurance increases across the Kingdom. Datamonitor forecasts this will result in a significant increase in overall expenditure on drugs; however there will be a greater shift towards generics use.

As competition increases, insurers will attempt to increase profits by implementing cost containment measures such as pharmacoeconomic drug evaluations, generic substitution and formulary lists. However, strong underwriting policies, optimal pricing premiums, and delivering quality care to members will remain critical.

Increasingly westernized lifestyles have driven up levels of chronic disease, enhancing the need for drug intervention, with lifestyle products dominating the retail market. Many branded drugs despite their off patent status still command market leading sales and positive growth, underlining the preference for branded drugs in the Saudi market.

Key reasons to purchase this research

• Understand the Saudi healthcare market and the strategic implications of future reforms and how these will affect your business
• Identify opportunities for mutually beneficial relationships between your firm and insurers which are becoming increasingly powerful stakeholders
• Gain insight into investment opportunities and create compelling cases for strategic changes in your organization to adapt to the evolving market

Table of Contents

EXECUTIVE SUMMARY

• Scope of the analysis
• Datamonitor insight into P&R in Saudi Arabia
• Key opinion leaders interviewed
• Related reports

OVERVIEW OF THE HEALTHCARE CHALLENGES IN SAUDI ARABIA

• Key findings
• Future challenges facing healthcare in Saudi Arabia
• The growing demographics of Saudi Arabia
• Chronic illnesses are a major concern for authorities in Saudi Arabia

HEALTHCARE FINANCING IN SAUDI ARABIA

• Key findings
• Access to healthcare in Saudi Arabia is currently patchy
• Private healthcare expenditure is set to grow
  • Healthcare in Saudi Arabia is primarily delivered through public channels
  • Controlling costs in the public sector
  • Change in distribution among private funding
• Healthcare reforms in Saudi Arabia aim to allow access to healthcare to all individuals
• Healthcare reforms transfer the burden of financing private sector employee healthcare from the Ministry of Health to employers
• Structural reforms seek to privatize hospitals

HEALTH INSURANCE IN SAUDI ARABIA

• Key findings
• Private versus public healthcare in Saudi Arabia
• The basic private health insurance coverage stipulated for Saudi Arabia is the best in the region
• The Saudi insurance market will be a strategic growth area as nationals are included
• The cooperative health insurance sector is a strategic growth area in Saudi Arabia
  • The Saudi healthcare insurance sector is well-regulated
  • Key factors affecting growth in the burgeoning Saudi healthcare insurance market

THE SAUDI ARABIAN PHARMACEUTICAL MARKET

• Key findings
• Pharmaceutical market dynamics in Saudi Arabia
  • European drugs dominate the imports in Saudi Arabia
• Saudi generics manufacturers face a number of barriers to growth
  • Generic drugs are widely used in the public sector, but not in the private sector
  • Pricing of generics and strong competition limits revenues
  • Misleading information on generic medicine inserts impacts uptake
  • Pharmacists play a significant and often unregulated role in dispensing of brands over generics
  • Patients are pressurizing physicians to prescribe generics
  • Physicians in Saudi Arabia tend to overprescribe, use trade names and are highly influenced by medical representatives
• Drug sales growth experienced across all therapy areas in Saudi Arabia
  • An increasingly westernized lifestyle has increased the prevalence of chronic diseases and the dependence on drugs
  • Lifestyle products dominate the Saudi retail market
• Saudi Arabia is dominated by Big Pharma and regional generics manufacturers
  • Domestic generics player are a key threat to international pharma companies operating in Saudi Arabia
  • Inorganic growth has been a successful growth strategy to date
  • Saudi Arabia incentivizes local manufacturing
  • Opportunities for clinical trials to generate region-specific pharmacoeconomic data in the kingdom
  • Companies should establish direct relationships with payers to ensure formulary inclusion and maximum reimbursement
  • Saudi Arabia offers generous endowments for research partnerships

HEALTHCARE REGULATORY AND GOVERNMENTAL ORGANIZATIONS

• Key findings
• The healthcare sector in Saudi Arabia consists of a complex network of regulators
  • Gulf Co-operative Council Health Ministers' Council has been a platform for developing healthcare in the region
  • Gulf Central Committee for Drug Registration
  • Bulk purchasing of drugs has been a powerful cost-saving mechanism for Gulf Cooperation Council governments
• The Ministry of Health is currently undergoing a transition towards a more regulatory role
  • Ministry of Health vaccination programs present opportunities for vaccine manufacturers
  • Combating diabetes will be one of the Ministry of Health' s key regulatory roles
  • Improving primary healthcare through family physicians
• The Saudi Food and Drug Authority' s role is to improve regulatory and approval processes
  • Drug approval is relatively straightforward in Saudi Arabia
  • Concerns over intellectual property protection has placed Saudi Arabia on the PhRMA Priority Watch List for 2009
  • The Saudi national drug code is the first step in the development of a unified healthcare management system in the kingdom
• The formation of the Council of Cooperative Health Insurance has strengthened development of the insurance industry
  • Future roles of the Council of Cooperative Health Insurance

PRICING AND REIMBURSEMENT IN SAUDI ARABIA

• Key findings
• Evolving pricing and reimbursement strategies in Saudi Arabia are required to control healthcare expenditure
  • The Ministry of Health controls drug prices in Saudi Arabia
  • Price adjustments were enacted by the Ministry of Health in 2008
• New SFDA recommendations for drug pricing guidelines proposed
  • Newly proposed changes to the common pricing criteria
  • Pricing guidelines for innovative drugs before and after patent expiry
  • Pricing guidelines for generic drugs
  • Proposed changes to the pricing of locally manufactured second branded drugs encourage contract manufacturing agreements
  • Pricing guidelines for drugs with more than one active ingredient
  • Saudi Food and Drug Authority recommends maximum price discounts on drugs with larger packaging size or dose strength
  • Additional new proposals submitted by the SFDA
• The use of pharmacoeconomic evaluations will change the face of Saudi drug reimbursement
  • Pharmacoeconomic evaluations are used globally
  • Pharmacoeconomics is sporadically used in Saudi Arabia presently
  • Saudi Arabia plans to integrate healthcare management centered around pharmacoeconomics

BIBLIOGRAPHY

• Journals and online articles

TABLES

• Table: Saudi Arabia: health economics indicators, 2009
• Table: Saudi hospital statistics, 2005 - 06
• Table: Forecast of Saudi private sector hospital market revenues, 2006 - 2015
• Table: Comparison of Saudi Arabia' s basic insurance plan (CCHI) with Abu Dhabi' s basic insurance plan (HAAD)
• Table: Top 10 pharmaceutical products in the retail market in Saudi Arabia, 2008
• Table: Detailed procedures in applications for marketing authorization from the Saudi Food and Drug Authority
• Table: Performance targets for Marketing Authorization Applications by the Saudi Food and Drug Authority
• Table: Proposed price reductions for package sizes and doses
• Table: List of 30 reference countries used by Saudi Arabia to price drugs
• Table: Exchange rates, 2009

FIGURES

• Figure: Projected population growth in Saudi Arabia, 2000 - 2015
• Figure: Deaths in Saudi Arabia by cause, all age groups, 2002
• Figure: Distribution of health service provision by region in Saudi Arabia, 2009
• Figure: Division of public and private expenditure on healthcare in Saudi Arabia, 2006
• Figure: The Saudi health system in comparison with selected pharmaceutical markets, 2009
• Figure: Healthcare service provision, by hospital beds, Saudi Arabia, 2005
• Figure: Shortcomings of the Ministry of Health in Saudi Arabia, 2009
• Figure: Private pre-paid plans and out-of-pocket expenditure as a percentage of private expenditure on healthcare in Saudi Arabia, 2002 - 06
• Figure: Implementation of mandatory health insurance in Saudi Arabia, 2009
• Figure: Comparison of the effect of the cooperative health insurance reforms on Saudi residents seeking treatment at public and private providers
• Figure: Number of insured individuals since the implementation of cooperative health insurance in Saudi Arabia, Q3 2006 - Q2 2008
• Figure: Saudi health insurance market growth, 2005 - 07
• Figure: Proposed direct relationship between insurers and pharmaceuticals in Saudi Arabia, 2009
• Figure: Growth of the Saudi Arabian pharmaceutical market, 2000 - 06
• Figure: Top 8 pharmaceutical exporting countries to Saudi Arabia, 2006
• Figure: Drug sales in the public and private pharmaceutical market in Saudi Arabia, 2007
• Figure: Proportion of physicians who feel pressured by patients to prescribe generic or branded drugs, 2008
• Figure: Physicians' source of information about generic alternatives versus branded drugs
• Figure: Proportion of physicians who support generic drug substitution, 2008
• Figure: Saudi retail pharmacy sales by ATC class, 2007 - 08
• Figure: Retail sales and growth of top 10 pharmaceutical companies in Saudi Arabia, 2007 - 08
• Figure: Leading domestic retail pharmaceutical manufacturers in Saudi Arabia, 2008
• Figure: Relationship between regulators, payers, providers, users, and suppliers, Saudi Arabia, 2009
• Figure: Six main components of Balsam project in Saudi Arabia
• Figure: Marketing Authorization process for generics, New Chemical Entities, biologics and orphan drugs
• Figure: The 11-digit Saudi National Drug Code
• Figure: Future challenges and strategy of the Council of Cooperative Health Insurance
• Figure: Global pricing and reimbursement strategies, 2009
• Figure: Profit margins for drugs in Saudi Arabia, 2004
• Figure: Comparison of retail drug prices in Saudi Arabia versus the United Arab Emirates, 2009
• Figure: Revised common pricing criteria proposed by the Saudi Food and Drug Authority, 2009
• Figure: Revised pricing guidelines for innovative drugs in Saudi Arabia
• Figure: Current and proposed new pricing guidelines for generic drugs in Saudi Arabia
• Figure: Suggestions and rationale for the pricing of generics in Saudi Arabia
• Figure: Suggestions and rationale for the pricing of drugs under license in Saudi Arabia
• Figure: Pricing guidelines for drugs with more than one active ingredient in Saudi Arabia
• Figure: Proposed healthcare management system in Saudi Arabia, 2009

相關商品

Datamonitor發行的製藥相關市場調查報告書

研究開發趨勢:心房纖維顫動患者預防中風用的抗凝血劑─即將上市的重量級新產品將留下永不消失的足跡

R&D Trends: Anticoagulants for stroke prevention in atrial fibrillation - Upcoming heavy hitters leave a permanent mark

價格 : US $ 3800

出版日期 : 2011年11月

Novartis AG:企業概要

Novartis AG: PharmaVitae Report

價格 : US $ 5700

出版日期 : 2011年11月

Novo Nordisk A/S:企業概要

Novo Nordisk A/S: PharmaVitae Profile

價格 : US $ 5700

出版日期 : 2011年11月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!